Investor Presentaiton

Novo Nordisk volume market shares in the three insulin segments 138 Investor presentation Full year 2022 NAO 60% Long-acting insulin Premix insulin Fast-acting insulin tMU MS tMU MS tMU MS 100 80% 80 80% 80 100% CAGR volume1: -0.3% CAGR volume1: -7.7% CAGR volume1: 1.5% MI penetration²: 65.2% 00 MI penetration²: 47.8% MI penetration²: 84.0% 80 80% 60% 60 60% 60 60 60 40 40 20 20 40% 40 20% 20 40% 40 20% 20 0% 0 Nov Nov 2022 2017 Segment volume FiaspⓇ 0 Nov 0% 0 Nov Nov 2017 2022 2017 Segment volume -LevemirⓇ Segment volume -TresibaⓇ -Combined NovoLog Mix share 70/30 1 CAGR for 5-year period; 2 Includes new-generation insulin. tMU: Thousand mega units; MS: Market Share Source: IQVIA monthly MAT, Nov 2022 volume figures NN: Novo Nordisk 40% 20% 0% Nov 2022 -NovoRapidⓇ NN combined

View entire presentation